DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE(1) trial): T cell responses and tumor infiltration correlate with tumor regression. Tanyi, J., Dorigo, O., Oza, A. M., Strauss, J., Pejovic, T., Ghamande, S. A., Ghatage, P., Villella, J. A., Fiset, S., MacDonald, L., Hrytsenko, O., Stanford, M., Newton, R. C., Leopold, L., Rosu, G. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.5576

View details for Web of Science ID 000487345805567